Black Diamond Sets Nov. 10 Webcast on Silevertinib Phase 2 Data and FDA-Backed Phase 3 Path
BDTX sits 22% above its 52-week low of $1.6.
Summary
Black Diamond will hold an investor webcast Tuesday, November 10, 2026 at 7:30 a.m. ET to present updated Phase 2 results for silevertinib in frontline EGFR-mutant NSCLC, along with FDA feedback that the company says supports a clear Phase 3 path toward potential accelerated approval. The headline is the FDA signal, not the data itself — no efficacy or safety numbers were disclosed in the release, so the actual Phase 2 update lands tomorrow morning. That matters for a micro-cap with a $1.95 stock and a cash runway the company cut to Q2 2027 in its last quarterly report; a credible accelerated-approval route is the difference between needing to raise money on weak terms and having a registrational story to finance against. The company says more than 200 patients have been treated with silevertinib across EGFR-mutant NSCLC and EGFR-altered GBM, and a separate randomized Phase 2 in newly diagnosed EGFRvIII-positive GBM is also running. Watch the 7:30 a.m. ET webcast for the response rate and durability figures that determine whether the Phase 3 plan holds up.
At the time of this announcement, BDTX was trading at $1.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $106.9M. The 52-week trading range was $1.60 to $4.94. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.